{"task_id": "2b8e16f519ebf533", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 378/464)", "text": "age, or shave removal\n370\nMelanoma and Skin Tumors\n\n--- Page 392 ---\nSPECIFIC ENTITIES (CONT\u2019D)\nVERRUCA VULGARIS (COMMON WARTS)\n\u0002\nPATHOPHYSIOLOGY\na human papillomavirus (HPV)\ninfection of keratinocytes. Lesions are benign but\nmay cause cosmetic concern and are increased in\nimmunocompromised individuals\n\u0002\nCLINICAL FEATURES\nlesions are well defined, firm\npapules or plaques with a hyperkeratotic cauli\nflower like or flat surface. Lesions may have brown\nblack dots which represent thrombosed capillaries.\nTypically occur over extremities and genital area.\nSpontaneous resolution within 6 months for 30%\nof patients and 2 years for 65% of patients\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nTREATMENTS\nmanual\nparing\nof\nthe\nlesions,\ncryotherapy, topical salicylic acid (e.g. salicylate\ncream 40% daily with glutaraldehyde 10 25%\ndaily),\nimiquimod,\n5 fluorouracil,\ncantharidin,\npodophylin,\nlaser\ntherapy,\nand\nintralesional\nbleomycin\nVITILIGO\n\u0002\nPATHOPHYSIOLOGY\nautoimmune process against\nmelanocytes. Differential diagnoses include tinea,\nleprosy, morphea, lichen sclerosus, post inflamma\ntory hypopigmentation, and chemicals\n\u0002\nCLINICAL FEATURES\nhypopigmented patch(es)\n\u0002\nTREATMENTS\ntopical steroids, UV light\nCutaneous Lupus Erythematosus\nDIFFERENTIAL DIAGNOSIS OF PHOTOSENSITIVITY\nIATROGENIC (DRUGS)\n\u0002\nAMIODARONE\n\u0002\nDIURETICS\nhydrochlorothiazide, loop\n\u0002\nANTIBIOTICS\ntetracycline\n\u0002 NSAIDs\n\u0002\nANTINEOPLASTIC\nmethotrexate, vincristine, 5\nfluorouracil\nINFLAMMATORY\nSLE, dermatomyositis\nIDIOPATHIC\npolymorphic light eruption, prur\nigo, actinic dermatitis, solar urticaria, chronic\nphotosensitivity dermatitis\nOTHERS\nphotocontact dermatitis, phytocontact\ndermatitis (celery, parsley, lime, lemon, yarrow),\nporphyria, xeroderma pigmentosum\nCLINICAL FEATURES\nCUTANEOUS MANIFESTATION OF SLE\n\u0002\nMALAR RASH\n\u2018\u2018butterfly rash\u2019\u2019 in up to 50% of lupus\npatients. Erythema in a malar distribution over the\ncheeks and bridge of the nose that spares nasola\nbial folds, especially after UV exposure\n\u0002\nDISCORD LUPUS\nup to 50% of lupus patients. Dis\ncrete, erythematous, scaly plaques with follicular\nplugging over face, neck, and scalp, especially after\nUV exposure. May lead to central scars, atrophy,\ntelangiectasias, and hyper /hypopigmentation\n\u0002\nSUBACUTE CUTANEOUS LUPUS\nup to 10% of lupus\npatients. Erythematous, slightly scaly papules that\nevolve into a papulosquamous or annular lesion\nover shoulders, forearms, neck, and upper torso.\nUsually no follicular plugging, hyperkeratosis, atro\nphy, pigment changes, and scarring\n\u0002\nLUPUS\nPROFUNDUS\nfirm, painful nodules over\nscalp, face, arms, chest, back, thighs, and buttocks\n\u0002\nLUPUS TUMIDUS\nchronic violaceous papules and pla\nques or nodule lesions over areas exposed to the sun\nCLINICAL FEATURES (CONT\u2019D)\n\u0002\nBULLOUS LESIONS\nphotosensitivity\n\u0002\nLIVEDO RETICULARIS\nsee SPECIFIC DISORDERS\n\u0002\nNAIL LESIONS\nup to 25% of lupus patients. Changes\ninclude pitting, ridging, onycholysis and lunula (red\nness of half moon), periungual erythema\n\u0002\nMUCOUS MEMBRANE ULCERS\n\u0002\nLUPUS ALOPECIA\nINVESTIGATIONS\nBASIC\n\u0002\nBLOOD TESTS\nCBCD, ANA, ENA, dsDNA\nSPECIAL\n\u0002\nSKIN BIOPSY\n\u0002\nPORPHYRIA WORKUP\nporphyrin, urine porphyrin\nMANAGEMENT\nTREATMENT UNDERLYING CAUSE\nsun protec\ntion. Topical steroid ointments. Topical immunosup\npressants (tacrolimus). Antimalaria (hydroxychloro\nquine). Systemic immunosuppressants\nRelated Topics\nSystemic Lupus Erythematosus (p. 279)\nPorphyria (p. 421)\nSPECIFIC ENTITIES\nCENTRAL\nFACIAL\nTELANGIECTASIA\nOR\nERYTHEMA\ncommon causes include rosacea, der\nmatomyositis, SLE, dermatitis (seborrheic, atopic, con\ntact), glucocorticoid induced dermal atrophy, flushing\nTELANGIECTASIA\ncommon causes include sun\ndamage, aging, hypertension, alcoholism, diabetes,\nrosacea, amyloidosis, lupus, other rheumatic diseases,\nand ataxia telangiectasia\nCutaneous Lupus Erythematosus\n371", "text_length": 3781, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 378/464)", "type": "chunk", "chunk_index": 377, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.770797", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.771766", "status": "pending"}